Tina Marriott Larson Sells 3,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott Larson sold 3,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $6.76, for a total transaction of $20,280.00. Following the completion of the sale, the chief operating officer now directly owns 413,404 shares of the company’s stock, valued at $2,794,611.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tina Marriott Larson also recently made the following trade(s):

• On Thursday, October 26th, Tina Marriott Larson sold 3,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $5.63, for a total transaction of $16,890.00.
• On Thursday, September 28th, Tina Marriott Larson sold 3,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.72, for a total transaction of $23,160.00.
• On Thursday, August 24th, Tina Marriott Larson sold 3,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.66, for a total transaction of $25,980.00.

Recursion Pharmaceuticals Trading Up 5.7 %

Shares of RXRX stock opened at $7.05 on Monday. The company’s fifty day simple moving average is $6.78 and its 200-day simple moving average is $8.35. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The company has a market cap of $1.53 billion, a PE ratio of -4.83 and a beta of 0.12.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. lowered their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, November 13th. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System grew its holdings in Recursion Pharmaceuticals by 128.4% during the 2nd quarter. Arizona State Retirement System now owns 36,068 shares of the company’s stock valued at $269,000 after purchasing an additional 20,274 shares in the last quarter. Yong Rong HK Asset Management Ltd acquired a new position in Recursion Pharmaceuticals during the 2nd quarter worth $8,772,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Recursion Pharmaceuticals by 453.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 8,073 shares of the company’s stock valued at $60,000 after buying an additional 6,615 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 66.8% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 837,400 shares of the company’s stock valued at $6,255,000 after buying an additional 335,423 shares during the period. Finally, Baillie Gifford & Co. boosted its holdings in shares of Recursion Pharmaceuticals by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 25,135,530 shares of the company’s stock valued at $167,654,000 after buying an additional 314,680 shares during the period. 57.82% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.